Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 247 Show results per page	View Search Criteria \| Help With Results


1.		PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Completed				15 and over				Other				LAL-RI/96 NCT00494897

Last Modified: 11/1/1997


2.		Phase II/III Pilot Treatment of Pediatric Non-B, Non-T ALL in First Marrow Relapse (SIMAL #8): Intensive Re-Induction and Reconsolidation Chemotherapy with Subsequent Myeloablative Chemoradiotherapy and Rescue with Either Allogeneic or In Vitro-Purged Autologous Marrow (Summary Last Modified 11/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				under 21 at relapse				NCI				POG-9410 POG-SIMAL-8, POG-9410


3.		Phase II-III VCR/PRED/L-ASP Induction, CNS Therapy plus MTX vs 6-MP/MTX vs 6-MP/MTX/CTX vs 6-MP/MTX/CTX/ARA-C for Pediatric ALL

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				under 18								SJCRH-ALL-TT-8

Last Modified: 8/10/2007


4.		Phase II/III Pilot Combination Chemotherapy and Radiotherapy for Previously Untreated Childhood ALL with Poor Prognosis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				under 21				NCI				CCG-192P


5.		Phase II/III Combination Chemotherapy with VCR/PRED/ADR for Induction, VCR/PRED/ADR/L-ASP for Intensification, Cranial Irradiation plus Intrathecal MTX for CNS Prophylaxis, and POMP (PRED/VCR/MTX/6-MP) for Maintenance in Patients with ALL and AUL

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				no age specified				NCI				DFCI-77001 NCI-T83-1310D, T83-1310

Last Modified: 11/9/2005


6.		Phase II/III Randomized Study of Standard-Dose vs High-Dose MTX Followed by Induction and Continuation for Patients with ALL or AUL

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				no age specified								DFCI-81001 NCI-D82-018-0400, D82-018-0400

Last Modified: 3/14/2007


7.		Phase II/III Randomized Comparison of Up-Front Alternating Chemotherapy vs Up-Front Intensive 6-MP/MTX for Poor Prognosis Childhood ALL

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				1 to 20				NCI				POG-8698 POG-8698

Last Modified: 7/11/2007


8.		Phase II/III Randomized Study of MP/MTX vs DCF/MP/MTX in Patients with Relapsed T-ALL or T-NHL Who Achieve Second Remission Following Induction with PVDA (PRED/VCR/DNR/ASP)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				21 and under				NCI				POG-8862 POG-8862

Last Modified: 5/1/2000


9.		Phase II/III Pilot Study of Combination Chemotherapy for Children with ALL in Relapse after Treatment on BFM Protocols (Summary Last Modified 05/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				under 20								ARG-GATLA-1LLAREC90 NCI-F92-0006, NCT00002499

Last Modified: 5/7/2008


10.		Phase III Randomized Study of High Versus Standard Dose Methotrexate and High Dose Cytarabine and Asparaginase Rescue Versus Standard Dose Cytarabine and Teniposide During Intensive Continuation and Consolidation in Children with High Risk Acute Lymphocytic Leukemia: An ALinC #16 Study

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				1 to 21 at diagnosis				NCI				POG-9406 POG-ALINC-16/HR, POG-9406

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute